Is CT Perfusion Ready for Liver Cancer Treatment Evaluation?
J Am Coll Radiol. 2015 Jan;12(1):111-3. doi: 10.1016/j.jacr.2014.10.007.
Liapi E1, Mahesh M2, Sahani DV3.
Introduction
Over the past decade, a remarkable transformation in the field of liver cancer therapeutics has led to a shift from traditional cytotoxic chemotherapy to antiangiogenic therapies. Despite progress in the field of liver cancer therapeutics, the development of innovative quantitative imaging biomarkers that may rapidly and cost effectively assess tumor response to novel antiangiogenic therapies has lagged behind, increasing the need for further development [ 1 ].